2026 ASCO年会即将开启，骨髓瘤领域重磅研究抢先速览

第一作者（以下简称：一作）：JPaul Richardson | Dana-Farber Cancer Institute

英文标题：Mezigdomide, carfilzomib, and dexamethasone (MeziKd) vs carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): Results from the phase 3 SUCCESSOR-2 trial

中文标题：Mezigdomide联合卡非佐米及地塞米松（MeziKd）对比卡非佐米联合地塞米松（Kd）治疗复发/难治性多发性骨髓瘤（RRMM）：Ⅲ期 SUCCESSOR-2临床试验结果

一作：Cyrille Touzeau | University Hospital of Nantes

英文标题：Safety and efficacy of elranatamab as early intervention in patients with high-risk smoldering myeloma: First results from the phase 2 ERASMM (EMN34) study

中文标题：Elranatamab早期干预治疗高危冒烟型骨髓瘤患者的安全性与疗效：Ⅱ期ERASMM（EMN34）研究首次结果

一作：Saad Usmani | Memorial Sloan Kettering Cancer Center

英文标题：DREAMM-9 final analysis: Belantamab mafodotin (belamaf), bortezomib, lenalidomide, and dexamethasone (BVRd) for transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM)

中文标题：DREAMM-9最终分析：Belantamab mafodotin(belamaf)联合硼替佐米、来那度胺及地塞米松（BVRd）治疗不适合移植（TI）的初诊多发性骨髓瘤（NDMM）患者

一作：Mattia D'Agostino | Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino

英文标题：Impact of sustained MRD negativity for up to 5 years on long-term outcome of transplant-eligible newly diagnosed multiple myeloma patients enrolled in the randomized phase 2 FORTE trial

中文标题：持续MRD阴性长达5年对适合移植初诊多发性骨髓瘤患者长期预后的影响：来自随机Ⅱ期 FORTE研究的数据

一作：Roberto Mina | Winship Cancer Institute, Emory University; Division of Hematology, Department of Molecular Biotechnology and Health Sciences, AOU Città della Salute e della Scienza di Torino

英文标题：MajesTEC-9: A phase 3 randomized study of teclistamab monotherapy vs investigator’s choice of pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone (PVd/Kd) in patients (pts) with relapsed refractory multiple myeloma (RRMM)

中文标题：MajesTEC-9研究：Teclistamab对比研究者选择的泊马度胺+硼替佐米+地塞米松或卡非佐米+地塞米松方案（PVd/Kd）治疗复发/难治性多发性骨髓瘤（RRMM）患者的Ⅲ期随机对照研究

一作：Saurabh Chhabra | Mayo Clinic Arizona

英文标题：Etentamig in patients (pts) with relapsed/refractory multiple myeloma (RRMM) with prior exposure to B-cell maturation antigen (BCMA)–targeted therapy

中文标题：既往接受过B细胞成熟抗原（BCMA）靶向治疗的复发/难治性多发性骨髓瘤（RRMM）患者接受Etentamig治疗  

一作：Areej El-Jawahri | Massachusetts General Hospital

英文标题：Randomized controlled trial of a psychosocial digital application (THRIVE-MM) for patients living with multiple myeloma

中文标题：多发性骨髓瘤患者心理社会数字化干预应用程序（THRIVE-MM）的随机对照研究

一作：P. Joy Ho | Royal Prince Alfred Hospital and University of Sydney

英文标题：Updated results from inMMyCAR, the ongoing first-in-human phase 1 study of KLN-1010 in patients (pts) with relapsed and refractory multiple myeloma (RRMM)

中文标题：inMMyCAR研究更新结果：KLN-1010 用于复发/难治性多发性骨髓瘤（RRMM）患者的正在进行的首次人体Ⅰ期临床研究

一作：Peter Forsberg | Colorado Blood Cancer Institute

英文标题：Optec/Optal: A phase 2 study to evaluate outpatient (OP), step-up administration of teclistamab (Tec) or talquetamab (Tal) with prophylactic tocilizumab (prophyToci) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

中文标题：Optec/Optal研究：评估门诊阶梯递增给药特立妥单抗或塔奎妥单抗联合预防性托珠单抗（prophyToci）治疗复发/难治性多发性骨髓瘤（RRMM）患者的Ⅱ期临床研究

一作：Joseph O'Brien | Denver Health Medical Center

英文标题：Survival outcomes comparing sequencing of CAR-T followed by BiTE versus BiTE followed by CAR-T in patients with relapsed multiple myeloma

中文标题：复发多发性骨髓瘤患者接受CAR-T细胞治疗序贯双特异性抗体对比双特异性抗体序贯CAR-T细胞治疗的生存结局对比分析

一作：Evangelos Terpos | Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine

英文标题：Belantamab mafodotin with daratumumab, lenalidomide, and dexamethasone in transplant-ineligible, newly diagnosed multiple myeloma patients: Phase 1/2 BelaDRd study

中文标题：Belantamab mafodotin联合达雷妥尤单抗、来那度胺及地塞米松治疗不适合移植初诊多发性骨髓瘤患者：Ⅰ/Ⅱ期BelaDRd研究

一作：Saad Usmani | Memorial Sloan Kettering Cancer Center

英文标题：Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients (pts) with newly diagnosed multiple myeloma (NDMM): Final analysis of transplant-ineligible (TIE) pts in the phase 3 CEPHEUS study

中文标题：达雷妥尤单抗联合硼替佐米、来那度胺及地塞米松（DVRd）治疗初诊多发性骨髓瘤（NDMM）患者：Ⅲ期CEPHEUS研究不适合移植患者（TIE）最终分析

一作：Prashant Kapoor | Mayo Clinic Rochester

英文标题：Efficacy and safety of iberdomide, daratumumab, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma

中文标题：Iberdomide联合达雷妥尤单抗、硼替佐米及地塞米松治疗初诊多发性骨髓瘤患者的疗效与安全性

一作：Suzanne Trudel | Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre

英文标题：Long-term outcomes with sustained minimal residual disease (MRD) negativity in belantamab mafodotin–treated patients (pts) with relapsed/refractory multiple myeloma (RRMM): An update from DREAMM-8

中文标题：Belantamab mafodotin治疗复发/难治性多发性骨髓瘤（RRMM）患者持续MRD阴性的长期结局：DREAMM-8研究更新数据

一作：Albert Oriol Rocafiguera | Institut Català d'Oncologia and Josep Carreras Research Institute, Hospital Germans Trias i Pujol

英文标题：Isatuximab plus pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: Subgroup analysis by prior anti-CD38 exposure from the phase 3 IRAKLIA trial

中文标题：艾沙妥昔单抗联合泊马度胺-地塞米松治疗复发/难治性多发性骨髓瘤：Ⅲ期IRAKLIA研究基于既往抗CD38治疗暴露的亚组分析

一作：Jennifer Cooperrider | University of Chicago

英文标题：Final analysis of daratumumab, carfilzomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma

中文标题：达雷妥尤单抗联合卡非佐米、泊马度胺及地塞米松治疗复发/难治性多发性骨髓瘤的最终分析

*ASCO官方摘要将持续更新，本文信息仅供参考，最新内容请以ASCO官网发布为准，如有疏漏，欢迎补充指正。